EptifibatideCardiovascularSafety Rating 8/10
Primary research areaAcute coronary syndrome
Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.
Research dose range180 mcg/kg bolus then 2 mcg/kg/min infusion
AdministrationIntravenous
Safety8/10 · FDA-approved (Integrilin)
NCAA D1Not listed
Price Comparison
Compare vendors
No vendor pricing available for this peptide yet.
Overview
About Eptifibatide
Mechanism of action
GP IIb/IIIa receptor inhibitor; prevents platelet aggregation via fibrinogen receptor blockade
Safety profile
Bleeding complications, thrombocytopenia, hypotension · Extensive use in cardiology; bleeding risk expected; thrombocytopenia rare
🔔 Get notified when the price drops anywhere
No account required. We scan 30+ vendors daily — one email the moment any vendor drops Eptifibatide below your target.
Related pages